Do you have a passion for Business Development?

Are you able to extract key insights from an analysis of the competitive landscape influencing oncology therapeutic area?

Consider joining SystImmune, one of the fastest growing biotech in the oncology space.

SystImmune is a US based clinical-stage biotech company founded in 2014 with R&D centers in Seattle, WA and Princeton, NJ.

Working closely with its parent company in China Biokin Pharmaceutical, SystImmune specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs).

The pipeline includes more than ten assets in clinical development for solid tumor and hematologic indications.

SystImmune is uniquely positioned to leverage drug development innovation ecosystem in the US and Biokin’s significant development infrastructure in China to ...